Superpharm petitions FDA
Executive Summary
On June 21, company asks FDA for a hearing on proposed withdrawal of ANDAs for diazepam. FDA proposed the withdrawal in a May 22 Federal Register notice, citing alleged "untrue statements of material facts" in the ANDAs. Superpharm stopped distributing diazepam in August 1989 and recalled the product on Dec. 5.